89Zr-Girentuximab
25-240
Phase 2 small_molecule active
Quick answer
89Zr-Girentuximab for Clear Cell Renal Cell Carcinoma (ccRCC) is a Phase 2 program (small_molecule) at Telix Pharmaceuticals Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Telix Pharmaceuticals Ltd
- Indication
- Clear Cell Renal Cell Carcinoma (ccRCC)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active